Omidria (Ketorolac)

Brand Name

Omidria

Generic Name

Ketorolac

View Brand Information

FDA approval date: June 13, 2014

Classification: alpha-1 Adrenergic Agonist

Form: Injection

What is Omidria (Ketorolac)?

Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. OMIDRIA is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for: Maintaining pupil size by preventing intraoperative miosis Reducing postoperative pain OMIDRIA is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Safety of Short-term NSAID Use in the Postoperative Setting in Pediatric Patients With Chronic Kidney Disease

Enrollment Status: Recruiting

Publish Date: June 08, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The purpose of this study is to determine if non-steroidal anti-inflammatory (NSAID) use in the postoperative setting increases the risk of acute kidney injury (AKI) in pediatric patients with mild-to-moderate chronic kidney disease (CKD). The investigators hypothesize that there is no increased risk. This is currently in the process of developing multi institution collaboration within a Pediatric...

Autonomic Control of the Circulation and the Venous Distension Reflex

Enrollment Status: Recruiting

Publish Date: June 02, 2026

Intervention Type: Other, Drug

Study Phase: Early Phase 1

Summary: The study objective of this project is to examine the mechanisms of the venous distension reflex (VDR) in humans. We hypothesize that COX blockade with ketorolac tromethamine, an intravenous NSAID, will attenuate the muscle sympathetic nerve activity (MSNA) response to limb venous distension. To gain further insight into whether the COX byproducts directly stimulate chemically-sensitive afferents,...

Intra-nasal Ketorolac Versus Oral Diclofenac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

Enrollment Status: Recruiting

Publish Date: May 27, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Objective: To improve quality-of-life and health care delivery to patients receiving ureteral stents. Specific

View All Clinical Trials

Related Latest Advances

Preemptive Analgesia With Steroidal and Nonsteroidal Anti-Inflammatory Drugs in Dental Implant Surgeries: A Systematic Review.

Journal: The Journal of oral implantology

Published: June 04, 2026

Quadratus Lumborum Block During Minimally Invasive Colorectal Surgery: A Tool for Enhanced Recovery.

Journal: Diseases of the colon and rectum

Published: June 02, 2026

An Update on Pain Management in Pediatric Spine Surgery.

Journal: Current reviews in musculoskeletal medicine

Published: May 14, 2026

View All Latest Advances

Brand Information

Omidria (phenylephrine and ketorolac)

1INDICATIONS AND USAGE

Omidria

2DOSAGE AND ADMINISTRATION

Omidria must be diluted prior to intraocular use. For administration to patients undergoing cataract surgery or intraocular lens replacement, 4 mL of Omidria is diluted in 500 mL of ocular irrigating solution. Irrigation solution is to be used as needed for the surgical procedure for a single patient.

The storage period for the diluted product is not more than 4 hours at room temperature or 24 hours under refrigerated conditions.

Do not use if the solution is cloudy or if it contains particulate matter.

3DOSAGE FORMS AND STRENGTHS

Omidria is an intraocular solution containing 10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac for use in a single patient.

4CONTRAINDICATIONS

Omidria is contraindicated in patients with a known hypersensitivity to any of its ingredients.

5OVERDOSAGE

Systemic overdosage of phenylephrine may cause a rise in blood pressure. It may also cause headache, anxiety, nausea, vomiting, and ventricular arrhythmias. Supportive care is recommended.

6DESCRIPTION

Omidria is a sterile aqueous solution, containing the α

The descriptions and structural formulae are:

Phenylephrine Hydrochloride Drug Substance:

Figure 1: Chemical Structure for Phenylephrine HCl

Ketorolac Tromethamine Drug Substance:

Figure 2: Chemical Structure for Ketorolac Tromethamine

Omidria is a clear, colorless to slightly yellow, sterile solution concentrate with a pH of approximately 6.3.

Each vial of Omidria contains:

Actives: phenylephrine hydrochloride 12.4 mg/mL equivalent to 10.16 mg/mL of phenylephrine and ketorolac tromethamine 4.24 mg/mL equivalent to 2.88 mg/mL of ketorolac.

Inactives: citric acid monohydrate; sodium citrate dihydrate; water for injection; may include sodium hydroxide and/or hydrochloric acid for pH adjustment.

7HOW SUPPLIED/STORAGE AND HANDLING

Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is supplied in a clear, 5-mL glass, single-patient-use vial containing 4 mL of sterile solution, for addition to ocular irrigating solution.

Omidria is supplied in a multi-pack containing:

4 vials : NDC 62225-600-04 or

10 vials: NDC 62225-600-10

8PATIENT COUNSELING INFORMATION

Inform patients that they may experience sensitivity to light.

Omeros Corporation

OMIDRIA

9PRINCIPAL DISPLAY PANEL

NDC 62225-600-04

OMIDRIA^®

(phenylephrine and ketorolac intraocular solution)

1% / 0.3%

For Intraocular use.

Must Be Diluted.

Single-Patient vial

Sterile 4 mL

Quantity: 4

Rx Only